focus -WSS

focus

author：focus 2025-09-09 05:35:32 - browse：1

Senator Ron Wyden (D-OR) speaks with reporters in the Senate subway at the U.S. Capitol — Sen. Ron Wyden (D-Ore.) Drew Angerer/Getty Images

Senate Finance Committee members from both parties took aim Wednesday at insurance brokers that sell plans for large Medicare Advantage insurers.

Older adults at times have more than 100 plan options, and brokers help them choose the right one. But brokers can be incentivized by large insurance companies to aggressively sell plans that are a poor fit for the Medicare beneficiaries they’re supposed to help. Brokers also sometimes collect private information that they sell to multiple insurance companies. Those brokers tend to have a national scope, just like the large insurers they represent, compared to the independent, local brokers.

“They are big private marketing companies in the middle between seniors and their coverage,” Chairman Ron Wyden (D-Ore.) said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Covid misinformation case heads to Supreme Court

WSS

CRISPR base editing slashes cholesterol levels in monkeys

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Congressmen charge Covid hearing ‘could have been an email’

Do digital therapeutics have a future in medicine?

With Roe v Wade overturned, abortion providers work to adapt

Do digital therapeutics have a future in medicine?

focus

focus

knowledge

Heart attack and stroke risk calculators need revising

SAMSHA loosens regulations on methadone treatment centers

Sports medicine is finally prioritizing gender equality

The real point of Kenneth Smith’s execution by nitrogen gas

Heart attack and stroke risk calculators need revising

New oral drug delivery patch is modeled after octopus tentacles

Hollywood unions extend contract negotiations for actors

Cognito secures funding to test medical device for Alzheimer's

Trump demands the U.S. pay no more for drugs than other countries … again

What we owe ALS patients — and why one company fell short

focus

Experts study whether long Covid risk adds up with each reinfection

IVG is promising — but it won’t replace IVF quite yet

FDA drug safety: Singulair case shows systemic surveillance flaws

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

CRISPR base editing slashes cholesterol levels in monkeys

6 solutions to address cancer drug shortages and others

hotspot

hotspot

focus

focus